Table 1_Efficacy of Yupingfeng powder in the treatment of bronchial asthma in adults: a sy

A systematic review and meta-analysis of 20 randomized controlled trials published up to October 20, 2025, involving 1,896 adult participants with bronchial asthma. The study, conducted by Qianqian Zhang and adhering to PRISMA 2020 guidelines, evaluates the efficacy and safety of Yupingfeng Powder combined with conventional biomedical therapy. It reports on clinical response rates, pulmonary function parameters, and adverse events.

Use Cases

• Evaluate the clinical overall response rate of Yupingfeng Powder based on the reported risk ratio and confidence intervals.
• Assess improvements in pulmonary function based on FEV1, FVC, FEV1/FVC, and PEF standardized mean difference values.
• Analyze treatment safety based on the reported incidence of mild adverse events like gastrointestinal discomfort.
• Investigate sources of heterogeneity in clinical studies based on treatment duration and study year subgroup analyses.

Strengths

• Includes data from 20 randomized controlled trials with a total of 1,896 participants.
• Follows PRISMA 2020 guidelines and was registered in PROSPERO (CRD420251172600).
• Reports specific statistical outcomes including risk ratios, standardized mean differences, and I² values for heterogeneity.

Limitations

• The underlying data is presented as a summary document (DOCX); raw trial-level data is not provided.
• The dataset is very small (18.3 KB), indicating it contains summary results rather than a full research dataset.
• Column-level documentation is absent; field semantics must be inferred from the text.

Provenance

Source

Qianqian Zhang via figshare

Collection Method

Systematic review and meta-analysis of RCTs from seven databases including PubMed, Embase, and Cochrane Library.

Time Range

Studies included up to October 20, 2025.

Freshness

Last updated 2026-05-01 05:27:47